Author: admin

DelveInsight’s “Idiopathic Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Idiopathic Membranous Nephropathy, historical and forecasted epidemiology as well as the Idiopathic Membranous Nephropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Idiopathic Membranous Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Idiopathic Membranous Nephropathy Market Forecast

Some of the key facts of the Idiopathic Membranous Nephropathy Market Report: 

• The Idiopathic Membranous Nephropathy market size was valued approximately USD 220 million in 2022 (7MM + China) and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In October 2023, the US FDA awarded Breakthrough Therapy Designation to felzartamab for primary membranous nephropathy (PMN) following encouraging clinical results from M-PLACE, a Phase II study conducted by I-Mab partner HI-Bio.
• In June 2023, Cerium Pharmaceuticals revealed that the US FDA awarded orphan drug designation (ODD) to SNP-ACTH (1-39) Gel.
• According to research conducted by Storrar et al. (2022), a total of 178 individuals diagnosed with primary membranous nephropathy were tracked over a span of two decades. The findings revealed that remission, whether partial or complete, was attained in 134 patients (75.3%). Among them, 60 (33.7%) experienced spontaneous remission, while 74 (41.6%) achieved remission following treatment with immunosuppressive therapy. However, out of those who achieved remission, 57 individuals (42.5%) experienced a relapse of the condition.
• In 2023, it was observed that the number of individuals with Idiopathic Membranous Nephropathy in the United States stood at approximately 29,000. Projections indicate that this figure is expected to rise to 31,227 cases by the year 2034.
• In 2023, Japan recorded an estimated 16,000 cases of Idiopathic Membranous Nephropathy.
• In 2022, the United States had the largest share, approximately 41%, of prevalent cases of Idiopathic Membranous Nephropathy (IMN) among the 7 Major Markets (7MM).
• In 2022, EU4 and the UK collectively represented around 24,000 cases of Idiopathic Membranous Nephropathy (IMN), and it is anticipated that these numbers will rise by the year 2032.
• In 2022, France had the smallest prevalence of Idiopathic Membranous Nephropathy (IMN) cases among EU4 and the UK, with approximately 4,000 cases. According to DelveInsight’s projections, these cases are anticipated to rise by 2032.
• Key pharmaceutical companies actively engaged in the development of therapies for Membranous Nephropathy (MN) include Hoffmann-La Roche (with obinutuzumab), MorphoSys (fezlartamab), Cerium Pharmaceuticals (SNP-ACTH [1-39] Gel), BeiGene (zanubrutinib), and GlaxoSmithKline.
• Key Idiopathic Membranous Nephropathy Companies: MorphoSys, , Hoffmann-La Roche, BeiGene, Cerium Pharmaceuticals, Reistone Biopharma/Eternity Bioscience, GlaxoSmithKline, ValenzaBio/ACELYRIN, Genentech, Inc., Mallinckrodt, HI-Bio, Zai Lab Pty. Ltd., ACELYRIN Inc, Reistone Biopharma, and others
• Key Idiopathic Membranous Nephropathy Therapies: Felzartamab (MOR202), GAZYVA (obinutuzumab), BRUKINSA (zanubrutinib), SNP-ACTH (1-39) Gel, SHR1459 (edralbrutinib), BENLYSTA (belimumab), VB119, Rituximab, Repository Corticotropin Injection, MOR202, efgartigimod IV, VB119, SHR1459, and others
• The Idiopathic Membranous Nephropathy epidemiology based on gender analyzed that Membranous nephropathy has a predilection for males over females.
• The Idiopathic Membranous Nephropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Idiopathic Membranous Nephropathy pipeline products will significantly revolutionize the Idiopathic Membranous Nephropathy market dynamics.

Idiopathic Membranous Nephropathy Overview

Idiopathic Membranous Nephropathy (IMN) is a kidney disorder characterized by inflammation of the glomeruli, which are the small filtering units in the kidneys responsible for removing waste and excess fluids from the blood. In IMN, the glomeruli’s filtering membranes become thickened, and the condition is associated with the formation of immune deposits, specifically immunoglobulin G (IgG) antibodies, on the glomerular basement membrane.

Get a Free sample for the Idiopathic Membranous Nephropathy Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-imn-market

Idiopathic Membranous Nephropathy Epidemiology

Idiopathic Membranous Nephropathy (IMN) is a kidney disorder characterized by inflammation and thickening of the glomerular basement membrane, which is a critical component of the kidney’s filtering system. In IMN, the immune system mistakenly attacks the glomerular basement membrane, leading to proteinuria (excessive protein in the urine) and impaired kidney function.

Idiopathic Membranous Nephropathy Epidemiology Segmentation:

The Idiopathic Membranous Nephropathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Idiopathic Membranous Nephropathy
• Prevalent Cases of Idiopathic Membranous Nephropathy by severity
• Gender-specific Prevalence of Idiopathic Membranous Nephropathy
• Diagnosed Cases of Episodic and Chronic Idiopathic Membranous Nephropathy

Download the report to understand which factors are driving Idiopathic Membranous Nephropathy epidemiology trends @ Idiopathic Membranous Nephropathy Epidemiology Forecast

Idiopathic Membranous Nephropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Idiopathic Membranous Nephropathy market or expected to get launched during the study period. The analysis covers Idiopathic Membranous Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Idiopathic Membranous Nephropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Idiopathic Membranous Nephropathy Therapies and Key Companies

• Felzartamab (MOR202): MorphoSys
• GAZYVA (obinutuzumab): Hoffmann-La Roche
• BRUKINSA (zanubrutinib): BeiGene
• SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals
• SHR1459 (edralbrutinib): Reistone Biopharma/Eternity Bioscience
• BENLYSTA (belimumab): GlaxoSmithKline
• VB119: ValenzaBio/ACELYRIN
• Rituximab: Genentech, Inc.
• Repository Corticotropin Injection: Mallinckrodt
• MOR202: HI-Bio
• efgartigimod IV: Zai Lab Pty. Ltd.
• VB119: ACELYRIN Inc.
• SHR1459: Reistone Biopharma

Discover more about therapies set to grab major Idiopathic Membranous Nephropathy market share @ Idiopathic Membranous Nephropathy Treatment Landscape

Idiopathic Membranous Nephropathy Market Strengths

• The availability of assays for PLA2R antibodies has induced a dramatic change of the diagnostic strategy, owing to the very high specificity of anti-PLA2R antibody for the diagnosis of MN. 
• With better efficacy results, and proteinuria reduction observed in six months after therapy, MOR202 (felzartamab) is expected to emerge as a strong therapeutic candidate and generate decent market share.

Idiopathic Membranous Nephropathy Market Opportunities

• Absence of marketed therapy in treatment space along with increasing patient pool paves the way for pharma players to come up with efficacious and cost effective treatment options 
• High rate of progression and remission in patients with MN presents pharmaceutical companies with an opportunity to develop therapies to overcome the shortcomings and grab a highly untapped market.

Scope of the Idiopathic Membranous Nephropathy Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Idiopathic Membranous Nephropathy Companies: MorphoSys, , Hoffmann-La Roche, BeiGene, Cerium Pharmaceuticals, Reistone Biopharma/Eternity Bioscience, GlaxoSmithKline, ValenzaBio/ACELYRIN, Genentech, Inc., Mallinckrodt, HI-Bio, Zai Lab Pty. Ltd., ACELYRIN Inc, Reistone Biopharma, and others
• Key Idiopathic Membranous Nephropathy Therapies: Felzartamab (MOR202), GAZYVA (obinutuzumab), BRUKINSA (zanubrutinib), SNP-ACTH (1-39) Gel, SHR1459 (edralbrutinib), BENLYSTA (belimumab), VB119, Rituximab, Repository Corticotropin Injection, MOR202, efgartigimod IV, VB119, SHR1459, and others
• Idiopathic Membranous Nephropathy Therapeutic Assessment: Idiopathic Membranous Nephropathy current marketed and Idiopathic Membranous Nephropathy emerging therapies
• Idiopathic Membranous Nephropathy Market Dynamics: Idiopathic Membranous Nephropathy market drivers and Idiopathic Membranous Nephropathy market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Idiopathic Membranous Nephropathy Unmet Needs, KOL’s views, Analyst’s views, Idiopathic Membranous Nephropathy Market Access and Reimbursement 

To know more about Idiopathic Membranous Nephropathy companies working in the treatment market, visit @ Idiopathic Membranous Nephropathy Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Idiopathic Membranous Nephropathy Market Report Introduction

2. Executive Summary for Idiopathic Membranous Nephropathy

3. SWOT analysis of Idiopathic Membranous Nephropathy

4. Idiopathic Membranous Nephropathy Patient Share (%) Overview at a Glance

5. Idiopathic Membranous Nephropathy Market Overview at a Glance

6. Idiopathic Membranous Nephropathy Disease Background and Overview

7. Idiopathic Membranous Nephropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Idiopathic Membranous Nephropathy 

9. Idiopathic Membranous Nephropathy Current Treatment and Medical Practices

10. Idiopathic Membranous Nephropathy Unmet Needs

11. Idiopathic Membranous Nephropathy Emerging Therapies

12. Idiopathic Membranous Nephropathy Market Outlook

13. Country-Wise Idiopathic Membranous Nephropathy Market Analysis (2020–2034)

14. Idiopathic Membranous Nephropathy Market Access and Reimbursement of Therapies

15. Idiopathic Membranous Nephropathy Market Drivers

16. Idiopathic Membranous Nephropathy Market Barriers

17.  Idiopathic Membranous Nephropathy Appendix

18. Idiopathic Membranous Nephropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Idiopathic Membranous Nephropathy Market to Register Incremental Growth During the Forecast Period (2024-2034), Asserts DelveInsight | MorphoSys, , Hoffmann-La Roche, BeiGene, Cerium Pharma, Reistone

DelveInsight’s “Metastatic HER2-positive Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Metastatic HER2-positive Breast Cancer, historical and forecasted epidemiology as well as the Metastatic HER2-positive Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Metastatic HER2-positive Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic HER2-positive Breast Cancer Market Forecast

Some of the key facts of the Metastatic HER2-positive Breast Cancer Market Report: 

• The Metastatic HER2-positive Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In January 2024, Processa Pharmaceuticals revealed its intentions to broaden the scope of Next Generation Capecitabine (NGC-Cap) development by including its application in the treatment of advanced or metastatic breast cancer, starting with the forthcoming Phase II trial. NGC-Cap involves the concurrent administration of PCS6422 and low doses of Capecitabine. The company aims to commence the Phase II study in the third quarter of 2024.
• As per the American Cancer Society’s latest data from 2023, breast cancer incidence rates have shown a consistent increase over the past four decades. Between 2010 and 2019, there was an annual rise of 0.5% in the incidence rate. However, from 2019 to 2023, there has been a notable acceleration in cases, with a growth rate of approximately 1.5%.
• According to studies by Tada et al. (2023) and Hayashi et al. (2020), the proportion of HR+/HER2+ and HR-/HER2+ breast cancer cases in Japan stands at approximately 60% and 40%, respectively.
• According to the analysis, approximately 44,700 new cases of HER2-positive breast cancer were reported in the US in 2023. It is anticipated that these numbers will experience a notable increase over the forecast period.
• In the US, a higher number of cases were identified for HR+/HER2+ breast cancer, totaling around 32,750 cases, compared to HR-/HER2+ cases, which accounted for only 11,900 patients in 2023, based on the hormonal status of women.
• Key Metastatic HER2-positive Breast Cancer Companies: Ambrx, Zymeworks/Jazz Pharmaceuticals, Roche, Criterium, Inc., Seagen Inc., Sichuan Baili Pharma, BioInvent International AB, Jiangsu HengRui Medicine, AstraZeneca, Bolt Biotherapeutics, Inc., DualityBio Inc., Yuhan Corporation, RemeGen Co., Ltd., Alliance Foundation Trials, LLC., SOLTI Breast Cancer Research Group, and others
• Key Metastatic HER2-positive Breast Cancer Therapies: ARX788, Zanidatamab zovodotin, Giredestrant, Alpelisib, Tucatinib, BL-M07D1, BI-1607, pyrotinib, Trastuzumab deruxtecan, BDC-1001, DB-1303/BNT323, YH32367, RC48-ADC, palbociclib, Ribociclib + Letrozole OR Fulvestrant, and others 
• The Metastatic HER2-positive Breast Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic HER2-positive Breast Cancer pipeline products will significantly revolutionize the Metastatic HER2-positive Breast Cancer market dynamics.

Metastatic HER2-positive Breast Cancer Overview

Metastatic HER2-positive breast cancer refers to breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body, such as the bones, liver, lungs, or brain, and is characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. HER2-positive breast cancer tends to be more aggressive than other types of breast cancer.

Get a Free sample for the Metastatic HER2-positive Breast Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/metastatic-her2-positive-breast-cancer-market 

Metastatic HER2-positive Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Metastatic HER2-positive Breast Cancer Epidemiology Segmentation:

The Metastatic HER2-positive Breast Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Metastatic HER2-positive Breast Cancer
• Prevalent Cases of Metastatic HER2-positive Breast Cancer by severity
• Gender-specific Prevalence of Metastatic HER2-positive Breast Cancer
• Diagnosed Cases of Episodic and Chronic Metastatic HER2-positive Breast Cancer

Download the report to understand which factors are driving Metastatic HER2-positive Breast Cancer epidemiology trends @ Metastatic HER2-positive Breast Cancer Epidemiology Forecast

Metastatic HER2-positive Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic HER2-positive Breast Cancer market or expected to get launched during the study period. The analysis covers Metastatic HER2-positive Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Metastatic HER2-positive Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Metastatic HER2-positive Breast Cancer Therapies and Key Companies

• ARX788: Ambrx
• Zanidatamab zovodotin: Zymeworks/Jazz Pharmaceuticals
• Giredestrant: Roche
• Alpelisib: Criterium, Inc.
• Tucatinib: Seagen Inc.
• BL-M07D1: Sichuan Baili Pharma
• BI-1607: BioInvent International AB
• pyrotinib: Jiangsu HengRui Medicine
• Trastuzumab deruxtecan: AstraZeneca
• BDC-1001: Bolt Biotherapeutics, Inc.
• DB-1303/BNT323: DualityBio Inc.
• YH32367: Yuhan Corporation
• RC48-ADC: RemeGen Co., Ltd.
• palbociclib: Alliance Foundation Trials, LLC.
• Ribociclib + Letrozole OR Fulvestrant: SOLTI Breast Cancer Research Group

Discover more about therapies set to grab major Metastatic HER2-positive Breast Cancer market share @ Metastatic HER2-positive Breast Cancer Treatment Landscape 

Metastatic HER2-positive Breast Cancer Market Drivers

• Strong uptake of Daiichi/Astra’s ENHERTU in second and third-line metastatic patients, owing to the unprecedented PFS any therapy in later lines could have ever achieved.
• Therapies for treating patients whose disease is resistant or refractory to prior HER2 treatment can potentially change the market dynamics in later-line settings.

Metastatic HER2-positive Breast Cancer Market Barriers

• As the current landscape of HER2+ is already packed with old aged blockbuster therapies, companies such as Ambrx BioPharma are developing novel therapies, aiming to target ENHERTU treated patients
• Despite the treatment with ADCs, around 20–30% of patients progress within 12 months, so there can be a significant market opportunity for therapies targeting these patients.

Scope of the Metastatic HER2-positive Breast Cancer Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Metastatic HER2-positive Breast Cancer Companies: Ambrx, Zymeworks/Jazz Pharmaceuticals, Roche, Criterium, Inc., Seagen Inc., Sichuan Baili Pharma, BioInvent International AB, Jiangsu HengRui Medicine, AstraZeneca, Bolt Biotherapeutics, Inc., DualityBio Inc., Yuhan Corporation, RemeGen Co., Ltd., Alliance Foundation Trials, LLC., SOLTI Breast Cancer Research Group, and others
• Key Metastatic HER2-positive Breast Cancer Therapies: ARX788, Zanidatamab zovodotin, Giredestrant, Alpelisib, Tucatinib, BL-M07D1, BI-1607, pyrotinib, Trastuzumab deruxtecan, BDC-1001, DB-1303/BNT323, YH32367, RC48-ADC, palbociclib, Ribociclib + Letrozole OR Fulvestrant, and others
• Metastatic HER2-positive Breast Cancer Therapeutic Assessment: Metastatic HER2-positive Breast Cancer current marketed and Metastatic HER2-positive Breast Cancer emerging therapies
• Metastatic HER2-positive Breast Cancer Market Dynamics: Metastatic HER2-positive Breast Cancer market drivers and Metastatic HER2-positive Breast Cancer market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Metastatic HER2-positive Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic HER2-positive Breast Cancer Market Access and Reimbursement 

To know more about Metastatic HER2-positive Breast Cancer companies working in the treatment market, visit @ Metastatic HER2-positive Breast Cancer Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Metastatic HER2-positive Breast Cancer Market Report Introduction

2. Executive Summary for Metastatic HER2-positive Breast Cancer

3. SWOT analysis of Metastatic HER2-positive Breast Cancer

4. Metastatic HER2-positive Breast Cancer Patient Share (%) Overview at a Glance

5. Metastatic HER2-positive Breast Cancer Market Overview at a Glance

6. Metastatic HER2-positive Breast Cancer Disease Background and Overview

7. Metastatic HER2-positive Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic HER2-positive Breast Cancer 

9. Metastatic HER2-positive Breast Cancer Current Treatment and Medical Practices

10. Metastatic HER2-positive Breast Cancer Unmet Needs

11. Metastatic HER2-positive Breast Cancer Emerging Therapies

12. Metastatic HER2-positive Breast Cancer Market Outlook

13. Country-Wise Metastatic HER2-positive Breast Cancer Market Analysis (2019–2032)

14. Metastatic HER2-positive Breast Cancer Market Access and Reimbursement of Therapies

15. Metastatic HER2-positive Breast Cancer Market Drivers

16. Metastatic HER2-positive Breast Cancer Market Barriers

17.  Metastatic HER2-positive Breast Cancer Appendix

18. Metastatic HER2-positive Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic HER2-positive Breast Cancer Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Ambrx, Zymeworks/Jazz Pharma, Roche, Criterium

DelveInsight’s “Guillain-Barré Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Guillain-Barré Syndrome, historical and forecasted epidemiology as well as the Guillain-Barré Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Guillain-Barré Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Guillain-Barré Syndrome Market Forecast

Some of the key facts of the Guillain-Barré Syndrome Market Report: 

• The Guillain-Barré Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In December 2023, Hansa Biopharma, known as “Hansa,” released encouraging preliminary findings from the phase 2 trial 15-HMedIdeS-09, showcasing the safety and tolerability of imlifidase alongside standard care. The trial demonstrated swift enhancements in disease-related effectiveness measures. Further evaluation of the efficacy data is scheduled for 2024. The 15-HMedIdeS-09 trial, designed as an open-label, single-arm study, evaluates the safety, tolerance, and efficacy of imlifidase in patients with Guillain-Barré Syndrome (GBS) in conjunction with standard intravenous immunoglobulin (IVIg) treatment.
• In October 2023, Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical firm specializing in novel complement-based therapies for autoimmune, neurodegenerative, and ophthalmic ailments, disclosed that the European Medicines Agency (EMA) has awarded orphan drug status to ANX005 for Guillain-Barré Syndrome (GBS) treatment. Previously, the U.S. Food and Drug Administration (FDA) had also granted ANX005 orphan drug status for GBS treatment.
• As per the National Organization of Rare Disorders (NORD) (n.d.), Guillain-Barré Syndrome (GBS) impacts approximately one to two individuals annually per 100,000 population. The precise cause of this condition remains uncertain. It’s noted that around half of those affected experience a gastrointestinal or respiratory infection in the days leading up to the onset of symptoms.
• The outlook for Guillain-Barré Syndrome (GBS) varies depending on its specific form. While some patients achieve full recovery, others may still face challenges with walking six months after the onset of the disease. In severe cases, GBS can unfortunately lead to a fatal outcome.
• Key Guillain-Barré Syndrome Companies: Chafic Karam, Hansa Biopharma AB, Annexon, and others
• Key Guillain-Barré Syndrome Therapies: Efgartigimod Alfa-Fcab, Imlifidase, ANX005, and others
• The Guillain-Barré Syndrome epidemiology based on gender analyzed that Guillain-Barré Syndrome is more common in men than in women
• The Guillain-Barré Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Guillain-Barré Syndrome pipeline products will significantly revolutionize the Guillain-Barré Syndrome market dynamics.

Guillain-Barré Syndrome Overview

Guillain-Barré Syndrome (GBS) is a rare neurological disorder where the body’s immune system mistakenly attacks its nerves. This condition leads to muscle weakness, numbness, and in some cases, paralysis. GBS often begins with tingling sensations and weakness in the legs, which can rapidly progress to affect the arms and upper body. In severe cases, GBS can cause paralysis of the entire body, including the muscles involved in breathing, requiring hospitalization and sometimes intensive care.

Get a Free sample for the Guillain-Barré Syndrome Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/guillain-barre-syndrome-gbs-market

Guillain-Barré Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Guillain-Barré Syndrome Epidemiology Segmentation:

The Guillain-Barré Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Guillain-Barré Syndrome
• Prevalent Cases of Guillain-Barré Syndrome by severity
• Gender-specific Prevalence of Guillain-Barré Syndrome
• Diagnosed Cases of Episodic and Chronic Guillain-Barré Syndrome

Download the report to understand which factors are driving Guillain-Barré Syndrome epidemiology trends @ Guillain-Barré Syndrome Epidemiology Forecast

Guillain-Barré Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Guillain-Barré Syndrome market or expected to get launched during the study period. The analysis covers Guillain-Barré Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Guillain-Barré Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Guillain-Barré Syndrome Therapies and Key Companies

• Efgartigimod Alfa-Fcab: Chafic Karam
• Imlifidase: Hansa Biopharma AB
• ANX005: Annexon, Inc.

Discover more about therapies set to grab major Guillain-Barré Syndrome market share @ Guillain-Barré Syndrome Treatment Landscape 

Scope of the Guillain-Barré Syndrome Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Guillain-Barré Syndrome Companies: Chafic Karam, Hansa Biopharma AB, Annexon, Inc., and others
• Key Guillain-Barré Syndrome Therapies: Efgartigimod Alfa-Fcab, Imlifidase, ANX005, and others
• Guillain-Barré Syndrome Therapeutic Assessment: Guillain-Barré Syndrome current marketed and Guillain-Barré Syndrome emerging therapies
• Guillain-Barré Syndrome Market Dynamics: Guillain-Barré Syndrome market drivers and Guillain-Barré Syndrome market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Guillain-Barré Syndrome Unmet Needs, KOL’s views, Analyst’s views, Guillain-Barré Syndrome Market Access and Reimbursement 

To know more about Guillain-Barré Syndrome companies working in the treatment market, visit @ Guillain-Barré Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Guillain-Barré Syndrome Market Report Introduction

2. Executive Summary for Guillain-Barré Syndrome

3. SWOT analysis of Guillain-Barré Syndrome

4. Guillain-Barré Syndrome Patient Share (%) Overview at a Glance

5. Guillain-Barré Syndrome Market Overview at a Glance

6. Guillain-Barré Syndrome Disease Background and Overview

7. Guillain-Barré Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Guillain-Barré Syndrome 

9. Guillain-Barré Syndrome Current Treatment and Medical Practices

10. Guillain-Barré Syndrome Unmet Needs

11. Guillain-Barré Syndrome Emerging Therapies

12. Guillain-Barré Syndrome Market Outlook

13. Country-Wise Guillain-Barré Syndrome Market Analysis (2019–2032)

14. Guillain-Barré Syndrome Market Access and Reimbursement of Therapies

15. Guillain-Barré Syndrome Market Drivers

16. Guillain-Barré Syndrome Market Barriers

17.  Guillain-Barré Syndrome Appendix

18. Guillain-Barré Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Guillain-Barré Syndrome Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Chafic Karam, Hansa Biopharma AB, Annexon

DelveInsight’s “Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Fragile X Syndrome, historical and forecasted epidemiology as well as the Fragile X Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Fragile X Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fragile X Syndrome Market Forecast

Some of the key facts of the Fragile X Syndrome Market Report: 

• The Fragile X Syndrome market size was valued approximately USD 45 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2023, the collective diagnosed prevalent cases of Fragile X Syndrome (FXS) across the seven major markets (7MM) were estimated to be approximately 123,000. Specifically, within the United States, there were approximately 71,000 diagnosed prevalent cases of FXS.
• In 2023, within the United States, approximately 60% of the prevalent cases of Fragile X Syndrome were reported in males, while nearly 40% were identified in females.
• Key Fragile X Syndrome Companies: Zynerba Pharmaceuticals, Confluence Pharmaceuticals, Tetra Therapeutics, Neuren Pharmaceuticals, Healx, Craig Erickson, Zynerba Pharmaceuticals, Nova Mentis Life Science, and others
• Key Fragile X Syndrome Therapies: Zygel, Acamprosate, BPN14770, Trofinetide, Sulindac (HLX-0201), Gaboxadol, ZYN002, Psilocybin, and others
• The Fragile X Syndrome epidemiology based on gender analyzed that males are affected more as compared to females, in the case of Fragile X Syndrome (FXS)
• The Fragile X Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fragile X Syndrome pipeline products will significantly revolutionize the Fragile X Syndrome market dynamics.

Fragile X Syndrome Overview

Fragile X Syndrome is a genetic condition characterized by intellectual disability, behavioral and learning challenges, and various physical features. It is caused by a mutation in the FMR1 gene located on the X chromosome. This mutation leads to a reduction or absence of the FMR1 protein, which is essential for normal brain development. Fragile X Syndrome is the most common inherited cause of intellectual disability, affecting males more severely than females. 

Get a Free sample for the Fragile X Syndrome Market Report:

https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market

Fragile X Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Fragile X Syndrome Epidemiology Segmentation:

The Fragile X Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Fragile X Syndrome
• Prevalent Cases of Fragile X Syndrome by severity
• Gender-specific Prevalence of Fragile X Syndrome
• Diagnosed Cases of Episodic and Chronic Fragile X Syndrome

Download the report to understand which factors are driving Fragile X Syndrome epidemiology trends @ Fragile X Syndrome Epidemiology Forecast

Fragile X Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fragile X Syndrome market or expected to get launched during the study period. The analysis covers Fragile X Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Fragile X Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Fragile X Syndrome Therapies and Key Companies

• Zygel: Zynerba Pharmaceuticals
• Acamprosate: Confluence Pharmaceuticals
• BPN14770: Tetra Therapeutics
• Trofinetide: Neuren Pharmaceuticals
• Sulindac (HLX-0201): Healx
• Gaboxadol: Craig Erickson
• ZYN002: Zynerba Pharmaceuticals
• Psilocybin: Nova Mentis Life Science

Discover more about therapies set to grab major Fragile X Syndrome market share @ Fragile X Syndrome Treatment Market

Fragile X Syndrome Market Strengths

• Growing Research and development are increasing the demand for FXS treatment. 
• Advances in DNA technology, including CRISPRCas9, have been used to correct the expanded CGG repeat in induced pluripotent stem cells. Eventually, it might be possible to add these corrected stem cells into the central nervous systems of those with FXS

Fragile X Syndrome Market Opportunities

• The rise in the prevalence of FXS stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products to be profitable. 
• Increasing population gives a lucrative opportunity to increase the awareness and innovation of therapeutics to drive FXS market. 

Scope of the Fragile X Syndrome Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Fragile X Syndrome Companies: Zynerba Pharmaceuticals, Confluence Pharmaceuticals, Tetra Therapeutics, Neuren Pharmaceuticals, Healx, Craig Erickson, Zynerba Pharmaceuticals, Nova Mentis Life Science, and others
• Key Fragile X Syndrome Therapies: Zygel, Acamprosate, BPN14770, Trofinetide, Sulindac (HLX-0201), Gaboxadol, ZYN002, Psilocybin, and others
• Fragile X Syndrome Therapeutic Assessment: Fragile X Syndrome current marketed and Fragile X Syndrome emerging therapies
• Fragile X Syndrome Market Dynamics: Fragile X Syndrome market drivers and Fragile X Syndrome market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Fragile X Syndrome Unmet Needs, KOL’s views, Analyst’s views, Fragile X Syndrome Market Access and Reimbursement 

To know more about Fragile X Syndrome companies working in the treatment market, visit @ Fragile X Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Fragile X Syndrome Market Report Introduction

2. Executive Summary for Fragile X Syndrome

3. SWOT analysis of Fragile X Syndrome

4. Fragile X Syndrome Patient Share (%) Overview at a Glance

5. Fragile X Syndrome Market Overview at a Glance

6. Fragile X Syndrome Disease Background and Overview

7. Fragile X Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Fragile X Syndrome 

9. Fragile X Syndrome Current Treatment and Medical Practices

10. Fragile X Syndrome Unmet Needs

11. Fragile X Syndrome Emerging Therapies

12. Fragile X Syndrome Market Outlook

13. Country-Wise Fragile X Syndrome Market Analysis (2020–2034)

14. Fragile X Syndrome Market Access and Reimbursement of Therapies

15. Fragile X Syndrome Market Drivers

16. Fragile X Syndrome Market Barriers

17.  Fragile X Syndrome Appendix

18. Fragile X Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fragile X Syndrome Market to Witness Growth by 2032, Estimates DelveInsight | Novartis, Neuren Pharma, Roche, Seaside Therapeutics, Inc., Marinus Pharma, Lysogene

The Food Allergy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Food Allergy Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Food Allergy Market.

Some of the key takeaways from the Food Allergy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Food Allergy treatment therapies with a considerable amount of success over the years. 
• Food Allergy companies working in the treatment market are Intrommune Therapeutics, Xencor, Vedanta Biosciences, Alladapt Immunotherapeutics, Aravax, Regeneron, DBV Technologies, Novartis AG, Camallergy, Genentech, GI Innovation, and others, are developing therapies for the Food Allergy treatment 

• Emerging Food Allergy therapies in the different phases of clinical trials are- INT301, AIMab7195, VE416, ADP101, PVX-108, Dupilumab, DBV 135, Ligelizumab, CA002, Omalizumab, GI 301, and others are expected to have a significant impact on the Food Allergy market in the coming years.   
• In November 2023, DBV Technologies announced new data on the use of Viaskin™ Peanut (DBV712). The data waspresented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, Anaheim, CA
• In March 2023, DBV Technologies initiated a Phase III, double-blind, placebo-controlled, randomized study toassess the efficacy and safety of epicutaneous immunotherapy with DBV712 250 μg in 4-7-year-old children with peanutallergy (VITESSE). The trial is currently active and recruiting the precipitants and is anticipated to be completed by March2025 with an enrollment of 600 participants.
• In November 2022, Omalizumab (Xolair), according to an ongoing phase 3 research known as OUtMATCH, is proving to be a successful medication for individuals with multiple food allergies, according to a Medpage report from the 2022 ACAAI meeting in Louisville, KY.
• In April 2022, According to a statement from Intrommune Therapeutics, the Maximum Tolerable Dose (MTD) has been adjusted for the ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy. Cohort 1 successfully increased the dosage to Dose 4 as previously announced, with no serious side effects. In order to find both an MTD and a safe beginning dose of INT301, patients with peanut allergies in Cohort 2 were started at Dose 2 and are being up-titrated through 11 escalating doses. Participants in Cohort 4 are anticipated to begin at Dose 4, while patients in Cohort 3 are beginning at Dose 3. Participants in Cohort 2 have successfully been up-titrated through 11 dosages. Enrollment for Cohort 3 is currently open. There haven’t been any noteworthy adverse incidents to date.
• In March 2022, Aravax reported that the U.S. Food and Drug Administration (FDA) had approved its application for an Investigational New Drug (IND). The next-generation allergen-specific immunotherapy PVX108 accurately targets the T cells responsible for peanut allergy by utilising peptides that stand in for important peanut protein components.

Food Allergy Overview

A food allergy is an adverse immune response triggered by consuming certain foods. When someone with a food allergy ingests the allergenic food, their immune system mistakenly identifies specific proteins in the food as harmful and releases chemicals such as histamine to defend against them. 

Get a Free Sample PDF Report to know more about Food Allergy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/food-allergy-pipeline-insight

Emerging Food Allergy Drugs Under Different Phases of Clinical Development Include:

• INT301: Intrommune Therapeutics
• AIMab7195: Xencor
• VE416: Vedanta Biosciences
• ADP101: Alladapt Immunotherapeutics
• PVX-108: Aravax
• Dupilumab: Regeneron
• DBV 135: DBV Technologies
• Ligelizumab: Novartis AG
• CA002: Camallergy
• Omalizumab: Genentech
• GI 301: GI Innovation

Food Allergy Route of Administration

Food Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Food Allergy Molecule Type

Food Allergy Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine 

Food Allergy Pipeline Therapeutics Assessment

• Food Allergy Assessment by Product Type
• Food Allergy By Stage and Product Type
• Food Allergy Assessment by Route of Administration
• Food Allergy By Stage and Route of Administration
• Food Allergy Assessment by Molecule Type
• Food Allergy by Stage and Molecule Type

DelveInsight’s Food Allergy Report covers around 35+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Food Allergy product details are provided in the report. Download the Food Allergy pipeline report to learn more about the emerging Food Allergy therapies

Some of the key companies in the Food Allergy Therapeutics Market include:

Key companies developing therapies for Food Allergy are – Merck & Co, AstraZeneca, Mabylon, GI Innovation, Aimmune Therapeutics, Inc, Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc, Vedanta Biosciences, Inc, Regeneron Pharmaceuticals, Genentech, Inc, Camallergy, Aravax, Inimmune, Prota therapeutics, Intrommune Therapeutics, Alladapt Immunotherapeutics, Siolta Therapeutics, IgGenix,  Rho Federal Systems Division, Inc, and many others.

Food Allergy Pipeline Analysis:

The Food Allergy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Food Allergy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Food Allergy Treatment.
• Food Allergy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Food Allergy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
•  Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Food Allergy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Food Allergy drugs and therapies

Food Allergy Pipeline Market Drivers

• Increasing prevalence of food allergies, growth in commercial and scientific activities for research and development are some of the important factors that are fueling the Food Allergy Market.

Food Allergy Pipeline Market Barriers

• However, lack of Public awareness, accurate diagnosis of food allergies is critical and other factors are creating obstacles in the Food Allergy Market growth.

Scope of Food Allergy Pipeline Drug Insight    

• Coverage: Global
• Key Food Allergy Companies: Intrommune Therapeutics, Xencor, Vedanta Biosciences, Alladapt Immunotherapeutics, Aravax, Regeneron, DBV Technologies, Novartis AG, Camallergy, Genentech, GI Innovation, and others
• Key Food Allergy Therapies: INT301, AIMab7195, VE416, ADP101, PVX-108, Dupilumab, DBV 135, Ligelizumab, CA002, Omalizumab, GI 301, and others
• Food Allergy Therapeutic Assessment: Food Allergy current marketed and Food Allergy emerging therapies
• Food Allergy Market Dynamics: Food Allergy market drivers and Food Allergy market barriers 

Request for Sample PDF Report for Food Allergy Pipeline Assessment and clinical trials

Table of Contents 

1. Food Allergy Report Introduction

2. Food Allergy Executive Summary

3. Food Allergy Overview

4. Food Allergy- Analytical Perspective In-depth Commercial Assessment

5. Food Allergy Pipeline Therapeutics

6. Food Allergy Late Stage Products (Phase II/III)

7. Food Allergy Mid Stage Products (Phase II)

8. Food Allergy Early Stage Products (Phase I)

9. Food Allergy Preclinical Stage Products

10. Food Allergy Therapeutics Assessment

11. Food Allergy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Food Allergy Key Companies

14. Food Allergy Key Products

15. Food Allergy Unmet Needs

16 . Food Allergy Market Drivers and Barriers

17. Food Allergy Future Perspectives and Conclusion

18. Food Allergy Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Food Allergy Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Novartis AG, Camallergy, Genentech, GI Innovation

“Type 1 Diabetes Market”

(Albany, USA) DelveInsight’s “Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Type 1 Diabetes, historical and forecasted epidemiology as well as the Type 1 Diabetes market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Type 1 Diabetes market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Type 1 Diabetes market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Type 1 Diabetes treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Type 1 Diabetes market.

Request for a Free Sample Report @ Type 1 Diabetes Market Forecast

Some facts of the Type 1 Diabetes Market Report are:

• According to DelveInsight, Type 1 Diabetes market size is expected to grow at a decent CAGR by 2032.
• Leading Type 1 Diabetes companies working in the market are Landos Biopharma, Zealand Pharma,  Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy,  SQZ Biotech, Enthera, and others.
• Key Type 1 Diabetes Therapies expected to launch in the market are LABP 111, TTP 399, Teplizumab, Emricasan, VX 880,  Encapsulated islet cell program, Eflornithine oral, Iscalimab, IMCY 0098, AT-1501, TOL 3021, AVT001, Volagidemab, NNC0363 0845, NNC0268-0965, LY 3209590, GP40071, Autoimmune diabetes vaccine, ProTrans, MHS 552, VC-02, OPT101, VC-01, Ladarixin, Aldesleukin, Stem Cell Educator therapy, ORMD-0801, ADO09, IMCY-0098, Glucagon intranasal, Golimumab, LY 900027, PRAM9JAG301,  Dasiglucagon, SQZ TAC research program, Ent001, and others.
• In July 2022, Vertex Pharmaceuticals announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320 million in cash.
• In April 2022, AVM Biotechnology received Small Business Innovation Research (SBIR) award of $1.6m from the National Institute of Diabetes and Digestive Kidney Disease (NIDDK) to study its small molecule, AVM0703, for reversing Type 1 diabetes (T1D). The latest grant will permit the company to carry out further research into using AVM0703 as a single agent and as a combination treatment for reversing recent onset and established T1D.

Type 1 Diabetes Overview

Type 1 diabetes is a chronic autoimmune condition where the immune system attacks and destroys insulin-producing beta cells in the pancreas. Insulin is crucial for regulating blood sugar (glucose) levels by facilitating its absorption into cells for energy. Without enough insulin, glucose accumulates in the bloodstream, leading to high blood sugar levels, which can cause various complications over time.

This condition typically develops during childhood or adolescence but can occur at any age. Its exact cause is unknown, but genetics and environmental factors play significant roles. Symptoms include frequent urination, increased thirst and hunger, weight loss, fatigue, and blurred vision.

Management of type 1 diabetes involves daily insulin injections or infusion via a pump, along with monitoring blood sugar levels, following a healthy diet, regular exercise, and careful management of other health conditions. Although there is currently no cure for type 1 diabetes, proper treatment and lifestyle adjustments can help individuals lead fulfilling lives while reducing the risk of complications.

Learn more about Type 1 Diabetes treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/type-1-diabetes-market

Type 1 Diabetes Market

The Type 1 Diabetes market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Type 1 Diabetes market trends by analyzing the impact of current Type 1 Diabetes therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Type 1 Diabetes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Type 1 Diabetes market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Type 1 Diabetes market in 7MM is expected to witness a major change in the study period 2019-2032.

Type 1 Diabetes Epidemiology

The Type 1 Diabetes epidemiology section provides insights into the historical and current Type 1 Diabetes patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Type 1 Diabetes market report also provides the diagnosed patient pool, trends, and assumptions. 

Explore more about Type 1 Diabetes Epidemiology @ Type 1 Diabetes Market Dynamics

Type 1 Diabetes Drugs Uptake

This section focuses on the uptake rate of the potential Type 1 Diabetes drugs recently launched in the Type 1 Diabetes market or expected to be launched in 2019-2032. The analysis covers the Type 1 Diabetes market uptake by drugs, patient uptake by therapies, and sales of each drug.

Type 1 Diabetes Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Type 1 Diabetes market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Type 1 Diabetes Pipeline Development Activities

The Type 1 Diabetes report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Type 1 Diabetes key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Type 1 Diabetes pipeline development activities @ https://www.delveinsight.com/sample-request/type-1-diabetes-market

Type 1 Diabetes Therapeutics Assessment

Major key companies are working proactively in the Type 1 Diabetes Therapeutics market to develop novel therapies which will drive the Type 1 Diabetes treatment markets in the upcoming years are Landos Biopharma, Zealand Pharma,  Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy,  SQZ Biotech, Enthera, and others.

Learn more about the emerging Type 1 Diabetes therapies & key companies @ https://www.delveinsight.com/sample-request/type-1-diabetes-market

Type 1 Diabetes Report Key Insights

1. Type 1 Diabetes Patient Population

2. Type 1 Diabetes Market Size and Trends

3. Key Cross Competition in the Type 1 Diabetes Market

4. Type 1 Diabetes Market Dynamics (Key Drivers and Barriers)

5. Type 1 Diabetes Market Opportunities

6. Type 1 Diabetes Therapeutic Approaches

7. Type 1 Diabetes Pipeline Analysis

8. Type 1 Diabetes Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Type 1 Diabetes Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Type 1 Diabetes Competitive Intelligence Analysis

4. Type 1 Diabetes Market Overview at a Glance

5. Type 1 Diabetes Disease Background and Overview

6. Type 1 Diabetes Patient Journey

7. Type 1 Diabetes Epidemiology and Patient Population

8. Type 1 Diabetes Treatment Algorithm, Current Treatment, and Medical Practices

9. Type 1 Diabetes Unmet Needs

10. Key Endpoints of Type 1 Diabetes Treatment

11. Type 1 Diabetes Marketed Products

12. Type 1 Diabetes Emerging Therapies

13. Type 1 Diabetes Seven Major Market Analysis

14. Attribute Analysis

15. Type 1 Diabetes Market Outlook (7 major markets)

16. Type 1 Diabetes Access and Reimbursement Overview

17. KOL Views on the Type 1 Diabetes Market

18. Type 1 Diabetes Market Drivers

19. Type 1 Diabetes Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Type 1 Diabetes Market and Epidemiology 2032: Clinical Trials, Therapies, FDA Approvals, Companies and Patient based Forecast by DelveInsight

“Diabetic Neuropathic Pain Market”

(New York, USA) DelveInsight’s “Diabetic Neuropathic Pain Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Diabetic Neuropathic Pain, historical and forecasted epidemiology as well as the Diabetic Neuropathic Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Diabetic Neuropathic Pain market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Diabetic Neuropathic Pain market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Diabetic Neuropathic Pain treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Diabetic Neuropathic Pain market.

Request for a Free Sample Report @ Diabetic Neuropathic Pain Market Forecast

Some facts of the Diabetic Neuropathic Pain Market Report are:

• According to DelveInsight, Diabetic Neuropathic Pain market size is expected to grow at a decent CAGR by 2032.
• Leading Diabetic Neuropathic Pain companies working in the market are AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo Co, Eli Lilly, GlaxoSmithKline, Glenmark Pharmaceuticals, Grunenthal, Helixmith Co, Lexicon Pharmaceuticals, Mitsubishi Tanabe Pharma Corp, Mundipharma, Novaremed AG, Novartis, Ono Pharmaceutical, Centrexion Therapeutics, Pfizer, Regenacy Pharmaceuticals, Sun Pharmaceutical Industries, Cymbalta, UCB, Viatris and others.
• Key Diabetic Neuropathic Pain Therapies expected to launch in the market are Duloxetine, CNTX-6016, MEDI 7352, and others.
• GSK3858279 Clinical Trial: A multicenter randomized, double-blind, placebo-controlled phase 2 study titled “A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain” is currently recruiting participants. The study aims to evaluate the efficacy, safety, tolerability, pharmacokinetics, and target engagement of GSK3858279 in adults with chronic Diabetic Peripheral Neuropathic Pain (DPNP). The estimated primary completion date is March 11, 2025.
• OPTION-DM Trial: The OPTION-DM trial, funded by the National Institute for Health Research (NIHR), is the largest and longest head-to-head, crossover neuropathic pain trial in the world. The findings from this trial are expected to inform future treatment guidelines for neuropathic pain in diabetes patients and chronic neuropathic pain treatment in general.

Diabetic Neuropathic Pain Overview

Diabetic neuropathic pain is a well-known complication of diabetes and the most common cause of all neuropathic pain. About one-third of all diabetes patients suffer from DNP. It is defined as the presence of signs and/or symptoms of nerve dysfunction in patients with diabetes after exclusion of other causes. Prolonged high blood sugar (glucose) level can injure nerves throughout your body however, legs and feet are the most affected by DNP.

Learn more about Diabetic Neuropathic Pain treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-dnp-market

Diabetic Neuropathic Pain Market

The Diabetic Neuropathic Pain market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Diabetic Neuropathic Pain market trends by analyzing the impact of current Diabetic Neuropathic Pain therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Diabetic Neuropathic Pain market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Diabetic Neuropathic Pain market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Diabetic Neuropathic Pain market in 7MM is expected to witness a major change in the study period 2019-2032.

Diabetic Neuropathic Pain Epidemiology

The Diabetic Neuropathic Pain epidemiology section provides insights into the historical and current Diabetic Neuropathic Pain patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Diabetic Neuropathic Pain market report also provides the diagnosed patient pool, trends, and assumptions. 

Explore more about Diabetic Neuropathic Pain Epidemiology @ https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-dnp-market

Diabetic Neuropathic Pain Drugs Uptake

This section focuses on the uptake rate of the potential Diabetic Neuropathic Pain drugs recently launched in the Diabetic Neuropathic Pain market or expected to be launched in 2019-2032. The analysis covers the Diabetic Neuropathic Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

Diabetic Neuropathic Pain Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Diabetic Neuropathic Pain market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Diabetic Neuropathic Pain Pipeline Development Activities

The Diabetic Neuropathic Pain report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Diabetic Neuropathic Pain key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Diabetic Neuropathic Pain pipeline development activities @ https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-dnp-market

Diabetic Neuropathic Pain Therapeutics Assessment

Major key companies are working proactively in the Diabetic Neuropathic Pain Therapeutics market to develop novel therapies which will drive the Diabetic Neuropathic Pain treatment markets in the upcoming years are AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo Co, Eli Lilly, GlaxoSmithKline, Glenmark Pharmaceuticals, Grunenthal, Helixmith Co, Lexicon Pharmaceuticals, Mitsubishi Tanabe Pharma Corp, Mundipharma, Novaremed AG, Novartis, Ono Pharmaceutical, Centrexion Therapeutics, Pfizer, Regenacy Pharmaceuticals, Sun Pharmaceutical Industries, Cymbalta, UCB, Viatris and others.

Learn more about the emerging Diabetic Neuropathic Pain therapies & key companies @ https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-dnp-market

Diabetic Neuropathic Pain Report Key Insights

1. Diabetic Neuropathic Pain Patient Population

2. Diabetic Neuropathic Pain Market Size and Trends

3. Key Cross Competition in the Diabetic Neuropathic Pain Market

4. Diabetic Neuropathic Pain Market Dynamics (Key Drivers and Barriers)

5. Diabetic Neuropathic Pain Market Opportunities

6. Diabetic Neuropathic Pain Therapeutic Approaches

7. Diabetic Neuropathic Pain Pipeline Analysis

8. Diabetic Neuropathic Pain Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Diabetic Neuropathic Pain Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Diabetic Neuropathic Pain Competitive Intelligence Analysis

4. Diabetic Neuropathic Pain Market Overview at a Glance

5. Diabetic Neuropathic Pain Disease Background and Overview

6. Diabetic Neuropathic Pain Patient Journey

7. Diabetic Neuropathic Pain Epidemiology and Patient Population

8. Diabetic Neuropathic Pain Treatment Algorithm, Current Treatment, and Medical Practices

9. Diabetic Neuropathic Pain Unmet Needs

10. Key Endpoints of Diabetic Neuropathic Pain Treatment

11. Diabetic Neuropathic Pain Marketed Products

12. Diabetic Neuropathic Pain Emerging Therapies

13. Diabetic Neuropathic Pain Seven Major Market Analysis

14. Attribute Analysis

15. Diabetic Neuropathic Pain Market Outlook (7 major markets)

16. Diabetic Neuropathic Pain Access and Reimbursement Overview

17. KOL Views on the Diabetic Neuropathic Pain Market

18. Diabetic Neuropathic Pain Market Drivers

19. Diabetic Neuropathic Pain Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Neuropathic Pain Market and Epidemiology 2032: Clinical Trials, Therapies, FDA Approvals, Companies and Patient based Forecast by DelveInsight

“Ulcerative Colitis Market”

DelveInsight’s Ulcerative Colitis Market report offers a detailed comprehension of the Ulcerative Colitis market size by treatment, epidemiology, and emerging therapies. The report also provides an understanding of Ulcerative Colitis market share of the individual therapies, current and forecasted Ulcerative Colitis market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

To know more in detail about Ulcerative Colitis Market report offerings, click here @ Ulcerative Colitis Market Forecast

Key highlights from the Ulcerative Colitis Market Insight report

• According to DelveInsight, the Ulcerative Colitis market size is expected to grow at a decent CAGR by 2032.

• The total Ulcerative Colitis Market Size in the 7MM was approximately USD 8090 million in 2022 and is projected to increase during the forecast period (2023–2032).
• In the United States, the total number of diagnosed prevalent cases of ulcerative colitis was 1,437,600 in 2022.

• Leading Ulcerative Colitis companies working proactively in the therapeutic market are Janssen Pharmaceuticals, Takeda Pharmaceuticals, Pfizer, EA Pharma, Kissei Pharma, Gilead Sciences, Galapagos NV, Celgene (Bristol-Myers Squibb), AbbVie, Arena Pharmaceuticals, Reistone Biopharma, Landos Biopharma, Bridge Biotherapeutics, Applied Molecular Transport, AbGenomics (AltruBio), Abivax, Connect Biopharma, Boehringer Ingelheim, Eli Lilly and Company, InDex Pharmaceuticals, Bristol-Myers Squibb, Protagonist Therapeutics, Mesoblast Ltd, and several others in the clinical development stage for Ulcerative Colitis will lead to a significant increase in the market size during the forecast period.
• The key Ulcerative Colitis therapies expected to launch in the market include Jyseleca (filgotinib), Rinvoq (Upadacitinib), Skyrizi (Risankizumab), Mirikizumab (LY-3074828),  Etrasimod, Tremfya (Guselkumab), Izencitinib (TD-1473/ JNJ 8398), BT-11, and others.

• According to DelveInsight analysis, the Ulcerative Colitis market is expected to rise in the coming years due to the entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/ advanced therapies, increasing prevalence of Ulcerative Colitis, and new biomarkers for diagnosis of Ulcerative Colitis.
• On January 2024, Palatin Technologies announced results of a Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, PK and Biomarkers with Oral Colon Delivery PL8177 in Adult Subjects with Active Ulcerative Colitis.
• On April 2024, Vedanta Biosciences announced results of A Phase 2 double-blind, placebo-controlled, randomized study to evaluate the safety, efficacy, and microbiota changes of VE202 in biologic-naïve patients with mild to moderate Ulcerative Colitis. In Parts 1 and 2 of the study, patients will receive VE202 or placebo for 8 weeks or 2 weeks. In Part 3, patients will be followed for safety for 1 year from the start of treatment.
• On March 2024, Eli Lilly announced results of a Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship with Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab.
• On February 2024, AbbVie announced results of a study about early therapeutic response and predictivity of long-term effectiveness of upadacitinib in ulcerative colitis (Europe).

For further information on Market Impact by Therapies, Download Ulcerative Colitis Market sample @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market

Ulcerative Colitis Overview

Two major types of Inflammatory Bowel Disease (IBD) are Ulcerative Colitis (UC) and Crohn’s Disease (CD). Ulcerative Colitis is limited to the colon or large intestine. Approximately 10% of cases of IBD exhibit the features of both Ulcerative Colitis and Crohn’s Disease. These are typically known as Indeterminate Colitis (IC). 

There are different types of Ulcerative Colitis, categorized by the cause of the disease: Ulcerative proctitis, Proctosigmoiditis, Left-sided colitis (also limited or distal colitis), Pancolitis, and Extensive Colitis. There is no single test to diagnose Ulcerative Colitis, instead, the IBD team takes into consideration the symptoms together with the results of Endoscopies, Biopsies, Blood and Stool tests, X-rays, and Imaging Procedures.

Ulcerative Colitis Epidemiology Segmentation

DelveInsight’s analysts indicate that the total diagnosed cases of Ulcerative Colitis in the 7MM were 1,577,979 in 2020. These cases are expected to rise by 2032, during the forecast period.

The Ulcerative Colitis market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Total Prevalent Ulcerative Colitis Cases
• Total Diagnosed Prevalent Ulcerative Colitis Cases
• Age-Specific Diagnosed Prevalent Cases of Ulcerative Colitis
• Severity-Specific Diagnosed Prevalent Cases of Ulcerative Colitis
• Total Treated Ulcerative Colitis Cases

Download Ulcerative Colitis Market sample to know more about the epidemiology and market trends @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market

Ulcerative Colitis Pipeline Therapies and Key Companies

• Jyseleca (filgotinib): Gilead Sciences/Galapagos NV
• Rinvoq (Upadacitinib) & Skyrizi(Risankizumab): AbbVie
• Risankizumab (ABBV-066): AbbVie and Boehringer Ingelheim
• Mirikizumab (LY-3074828): Eli Lilly and Company
• Etrasimod: Arena Pharmaceuticals
• Tremfya (Guselkumab): Janssen (Johnson & Johnson)
• Izencitinib (TD-1473/ JNJ 8398): Theravance Biopharma/Johnson & Johnson
• BT-11: Landos Biopharma 

Ulcerative Colitis Market Dynamics

The current therapeutic landscape of Ulcerative Colitis in the 7MM is driven by several approved therapies. Also, the Ulcerative Colitis market is expected to surge due to factors such as the increasing prevalence of Ulcerative Colitis, entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/ advanced therapies, new biomarkers for diagnosis of Ulcerative Colitis and also the involvement of digital technology for diagnosis and treatment.

A high number of undiagnosed and unreported cases contribute to the lack of awareness of Ulcerative Colitis. The entry of biosimilars in the Ulcerative Colitis Market, insufficient knowledge of the disease, and significant drawbacks of existing therapeutic options may act as certain obstructions in the Ulcerative Colitis market.

For further information on Market Impact by Therapies, Download Ulcerative Colitis Market sample @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market

Scope of the Ulcerative Colitis Market Report

• Study Period: 2019-32
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Ulcerative Colitis Companies: Takeda Pharmaceutical, Pfizer, Celgene (Bristol-Myers Squibb), Gilead Sciences, Galapagos NV, AbbVie, Eli Lilly and Company, Arena Pharmaceuticals, Janssen (Johnson & Johnson), Theravance Biopharma, Landos Biopharma
• Key Ulcerative Colitis Drugs: Jyseleca (filgotinib), Rinvoq (Upadacitinib), Skyrizi(Risankizumab), Mirikizumab (LY-3074828),  Etrasimod, Tremfya (Guselkumab), Izencitinib (TD-1473/ JNJ 8398), BT-11
• Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and emerging therapies
• Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and barriers 
• Competitive Intelligence Analysis: Porter’s five forces, SWOT analysis, PESTLE analysis, Market entry strategies, BCG Matrix, Unmet Needs
• KOL views
• Reimbursement Scenario

Download Market sample to know more about the recent happenings in the Ulcerative colitis therapeutic landscape @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market

Table of Contents 

1. Key Insights

2. Report Introduction of Ulcerative Colitis

3. Ulcerative Colitis Market Overview at a Glance

4. Executive Summary of Ulcerative Colitis

5. Ulcerative Colitis Epidemiology and Market Forecast Flow

6. Ulcerative Colitis: Disease Background and Overview

7.  Ulcerative Colitis Diagnosis

8. Ulcerative Colitis Current Treatment

9. Ulcerative Colitis Epidemiology and Patient Population

10. Ulcerative Colitis Patient Journey

11. Key Endpoints in Ulcerative Colitis Clinical Trials

12. Ulcerative Colitis Marketed Therapies of Ulcerative Colitis

13. Ulcerative Colitis Emerging Therapies

14. Conjoint Analysis of Ulcerative Colitis

15. Ulcerative Colitis: Seven Major Market Analysis

16. The United States Market Size

17. Ulcerative Colitis Market Access and Reimbursement

18. Ulcerative Colitis Market Drivers

19. Ulcerative Colitis Market Barriers

20. Ulcerative Colitis SWOT Analysis

21. Ulcerative Colitis Unmet Needs

22. Appendix

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

About DelveInsight

DelveInsight is a pioneer in stipulating state-of-the-art services to the clients, also serving as a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ulcerative Colitis Market Analysis 2032: Epidemiology, Market Size, Drugs, FDA Approval, Clinical Trials, Companies and Competitive Landscape by DelveInsight